Call Girls Jaipur Just Call 9521753030 Top Class Call Girl Service Available
Drug development in Alzheimer's Disease
1. FOCUSED. TRUSTED. GLOBAL.
EXPERTS
Drug Development in Alzheimer’s Disease
Challenges and Opportunities
Samer E. Kaba, M.D.
Medical Director – Neuroscience
Clinical Assistant Professor of Neurology
Emory University
2. FOCUSED. TRUSTED. GLOBAL.
Pathology
o AD is a degenerative disease characterized by:
Loss of neurons
Intracellular accumulation of neurofibrillary tangles
Accumulation of amyloid plaques
Brain and hippocampal atrophy
o Genetic factors have a definitive role
Multiple genes identified
o The pathological changes are similar to normal
aging qualitatively, but different quantitatively
5. FOCUSED. TRUSTED. GLOBAL.
Pathophysiology
o Protein Abnormalities in Alzheimer's Disease
β-Amyloid
Tau
o Synapse Related Abnormalities
Synaptic Failure
Depletion of Neurotrophin and Neurotransmitters
o Mitochondrial Dysfunction
Oxidative Stress
Insulin-Signaling Pathway
Vascular Effects
Inflammation
6. FOCUSED. TRUSTED. GLOBAL.
Clinical Presentation
o Cognitive decline
Short- term memory impairment
Confusion
Decreased visuo-spacial orientation
Reduced comprehension and other verbal skills
o Behavioral changes
Personality and mood changes
Sleep disturbance
Agitation
Paranoia and hallucinations
Loco-motor slowing
7. FOCUSED. TRUSTED. GLOBAL.
Therapeutic Targets
o Symptomatic treatments
Mostly neurotransmitters based
Existing therapies are all symptomatic
Can work in different stages of the disease
o Disease modifying therapies
None is available to date, the race is on…!
To target the changes leading to progressive tissue
damage and clinical manifestations
Early treatment is crucial
9. FOCUSED. TRUSTED. GLOBAL.
Current Outcome Measures
in AD Trials:
o Primary outcomes
Cognition -ADAS-cog
Global - CIBIC+
o Secondary Outcomes
Behavioral – NPI or BEHAVE-AD
ADL – DAD or ADCS-ADL
o Caregiver burden
Direct relationship to institutionalization of patient
o Pharmaco-economics
Complex but of increasing interest to governments and
third party payers
11. FOCUSED. TRUSTED. GLOBAL.
Disease Modifying Therapy
o No disease modifying therapy for AD is
available yet
o Slow progress because:
Difficulty in identifying therapeutic targets
Sub-optimal collaboration with academia
The lack of adequate animal models of AD
The limitations of standard clinical endpoints (ADAS-
Cog, MMSI, etc.)
The need for biomarkers of disease activity and tissue
injury
Tactical challenges to AD trials
12. FOCUSED. TRUSTED. GLOBAL.
Biomarkers of AD –
A Critical Need
o Providing surrogate measures for evaluating
compounds in early development (go-no-go
decisions)
o Confirming the eligibility of patients for trials
o Selecting homogeneous groups of patients
o Providing more objective endpoints for
confirmatory trials
o Confirming the clinical findings of confirmatory
controlled trials
o Illustrating a positive effect on tissue injury and
disease progression
13. FOCUSED. TRUSTED. GLOBAL.
Biomarkers of AD –Modalities
o Brain imaging
MRI:
• Volumetric MRI
• Functional MRI,
Nuclear:
• FDG-PET
• Amyloid imaging (PiB)
o Biological testing
Tau and P-tau protein in CSF
Amyloid βA4 in CSF
o Electrophysiology
Quantitative EEG (Brain Mapping)
Long latency evoked potentials
18. FOCUSED. TRUSTED. GLOBAL.
Outcome Measures
o Cognitive Measures
ADAS-Cog (Alzheimer Disease Assessment Scale –Cognitive
subscale)
MMSE (Mini Mental State Examination)
o Functional Rating Scales
ADCS-ADL (Alzheimer Disease Cooperative Study – Activities of
Daily Living)
o Global ratings of severity and change
CIBIC/CIBIS (Clinician Interview-based Impression of Change)
CDR (Clinical Dementia Rating)
19. FOCUSED. TRUSTED. GLOBAL.
ADAS-Cog Limitations
o Ceiling and floor effects
o Non-linear sensitivity
More sensitive in moderate disease
o Inter-rater and intra-rater variability
Rater training and drift should be considered in trials
o Change in scores do not always translate into
clinical benefit
o Prone to practice effect
Should not be administered frequently
20. FOCUSED. TRUSTED. GLOBAL.
Tactical Challenges in AD Trials
o Early disease:
Patients acceptance / motivation
The need for long-term follow up
Competing trials
o Moderate disease
Finding treatment naïve patients
Need for reliable caregiver
Co-morbidities
o Advanced Disease
Behavioral problems more pronounced
Institutionalized patients
Co-morbidities
Consent issues